UA120697C2 - Спосіб виміру активності природних клітин-кілерів (nk) у зразку цільної крові - Google Patents

Спосіб виміру активності природних клітин-кілерів (nk) у зразку цільної крові Download PDF

Info

Publication number
UA120697C2
UA120697C2 UAA201310947A UAA201310947A UA120697C2 UA 120697 C2 UA120697 C2 UA 120697C2 UA A201310947 A UAA201310947 A UA A201310947A UA A201310947 A UAA201310947 A UA A201310947A UA 120697 C2 UA120697 C2 UA 120697C2
Authority
UA
Ukraine
Prior art keywords
cells
interleukin
whole blood
blood sample
amino acid
Prior art date
Application number
UAA201310947A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джей Мюн Лі
Джэй Мюн Ли
Джу Чун Йун
Санг Ву Парк
Джонг Сун Кім
Джонг Сун Ким
Original Assignee
Нкмакс Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нкмакс Ко., Лтд. filed Critical Нкмакс Ко., Лтд.
Publication of UA120697C2 publication Critical patent/UA120697C2/uk

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
UAA201310947A 2011-02-14 2012-02-10 Спосіб виміру активності природних клітин-кілерів (nk) у зразку цільної крові UA120697C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110012983A KR20120093002A (ko) 2011-02-14 2011-02-14 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
PCT/IB2012/000259 WO2012110878A2 (en) 2011-02-14 2012-02-10 Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity

Publications (1)

Publication Number Publication Date
UA120697C2 true UA120697C2 (uk) 2020-01-27

Family

ID=46672988

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201310947A UA120697C2 (uk) 2011-02-14 2012-02-10 Спосіб виміру активності природних клітин-кілерів (nk) у зразку цільної крові

Country Status (20)

Country Link
US (2) US11442069B2 (enExample)
EP (1) EP2676139B1 (enExample)
JP (5) JP6629497B2 (enExample)
KR (3) KR20120093002A (enExample)
CN (1) CN103370622B (enExample)
AU (2) AU2012219184A1 (enExample)
BR (1) BR112013020454B1 (enExample)
CA (1) CA2826053C (enExample)
CL (1) CL2013002361A1 (enExample)
DK (1) DK2676139T3 (enExample)
EA (1) EA038959B1 (enExample)
ES (1) ES2797549T3 (enExample)
IL (1) IL227952B (enExample)
MX (1) MX361731B (enExample)
MY (1) MY175351A (enExample)
RU (1) RU2635194C2 (enExample)
SG (1) SG192247A1 (enExample)
TW (2) TWI668445B (enExample)
UA (1) UA120697C2 (enExample)
WO (1) WO2012110878A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
WO2015069187A1 (en) 2013-11-05 2015-05-14 Agency For Science, Technology And Research Bladder Carcinoma Biomarkers
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
WO2017204446A2 (ko) * 2016-05-24 2017-11-30 울산대학교 산학협력단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
CN106222140A (zh) * 2016-08-04 2016-12-14 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基及其配制方法
CN107686828A (zh) * 2016-08-04 2018-02-13 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
BR112019016374A2 (pt) 2017-02-17 2020-04-07 Bristol-Myers Squibb Company anticorpos para alfa-sinucleína e usos dos mesmos
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102090698B1 (ko) * 2017-08-24 2020-04-23 연세대학교 산학협력단 암의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법
JP7268039B2 (ja) 2018-02-01 2023-05-02 エヌケーマックス カンパニー リミテッド がん治療のためのナチュラルキラー細胞および組成物の製造方法
EP3924368A4 (en) * 2019-02-14 2022-12-14 Research Institute at Nationwide Children's Hospital USE OF A STIMULATING AGENT TO ANALYZE THE POTENCY OF IMMUNE CELLS
WO2021041399A1 (en) * 2019-08-29 2021-03-04 Board Of Regents, The University Of Texas System Cell cryopreservation medium
CN112552391B (zh) * 2019-09-25 2024-08-23 北京志道生物科技有限公司 一种重组白介素-15类似物
CN114929249A (zh) * 2019-11-29 2022-08-19 Nkmax有限公司 产生自然杀伤细胞及其组合物的方法
WO2022024693A1 (ja) * 2020-07-29 2022-02-03 国立大学法人東北大学 シヌクレイノパチーを予防又は治療するために使用されるペプチド
CN113533729B (zh) * 2021-06-15 2024-09-06 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
EP4448554A1 (en) * 2021-12-17 2024-10-23 University of Kent Sequences and methods for production of recombinant biological molecules in vesicles
KR20230156518A (ko) 2022-05-06 2023-11-14 (주)다이오진 엑소좀 내의 인터페론 감마 유전자 측정을 이용한 암 조기 진단 방법 및 진단 키트
CN115247149B (zh) * 2022-08-22 2023-06-16 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法
CN115855779A (zh) * 2023-01-18 2023-03-28 山东康华生物医疗科技股份有限公司 一种定量检测nk细胞活性的磁微粒化学发光试剂盒及其检测方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2635088A (en) * 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
HUT74425A (en) * 1993-08-09 1996-12-30 Baral A method for sensitization of cancer for killer cell mediated lysis
WO1996024369A1 (en) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7781210B2 (en) 2001-08-13 2010-08-24 Junjiro Tsuchiyama Epstein-Barr virus-negative NK cell line
EP1451217A4 (en) * 2001-11-20 2005-10-12 Atgen Co Ltd NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
AU2003220557A1 (en) * 2002-03-26 2003-10-13 Centocor, Inc. Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
JP2004305095A (ja) 2003-04-07 2004-11-04 Limuloid Science Kk 細胞活性化検出方法
CN1297567C (zh) * 2003-06-13 2007-01-31 马菁 具有抗肿瘤功能的双功能融合蛋白及其制备方法和应用
ATE500267T1 (de) * 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
WO2005013950A2 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
CA2542886A1 (en) 2003-11-05 2005-05-19 Neelima M. Bhat Enhanced b cell cytotoxicity of cdim binding antibody
KR100565764B1 (ko) * 2005-05-02 2006-03-28 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및 이를포함하는 융합 단백질
WO2005108423A1 (en) 2004-05-11 2005-11-17 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
JP4653465B2 (ja) 2004-10-25 2011-03-16 泰信 小林 ナチュラルキラー細胞の増殖促進方法およびそれに用いる培養組成物
EP1901766A2 (en) * 2005-04-08 2008-03-26 Morningside Venture Investments Limited Use of fril proteins for reducing the production of pro-inflammatory cytokines
WO2008013975A2 (en) * 2006-07-28 2008-01-31 The Research Foundation Of State University Of New York Methods and kits for measurement of lymphocyte function
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
CN101578113B (zh) 2007-01-11 2015-04-22 诺和诺德公司 抗-kir抗体、制剂及其应用
EP2048237A1 (en) * 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트

Also Published As

Publication number Publication date
TW201245718A (en) 2012-11-16
US12379384B2 (en) 2025-08-05
BR112013020454B1 (pt) 2023-03-21
US11442069B2 (en) 2022-09-13
BR112013020454A2 (pt) 2016-10-18
US20140017713A1 (en) 2014-01-16
JP6629497B2 (ja) 2020-01-15
SG192247A1 (en) 2013-09-30
KR101438573B1 (ko) 2014-09-12
ES2797549T3 (es) 2020-12-02
NZ614345A (en) 2015-09-25
JP2017129597A (ja) 2017-07-27
AU2017202628A1 (en) 2017-05-11
JP7660605B2 (ja) 2025-04-11
CA2826053A1 (en) 2012-08-23
RU2635194C2 (ru) 2017-11-09
TWI681191B (zh) 2020-01-01
JP2019207242A (ja) 2019-12-05
IL227952A0 (en) 2013-09-30
CA2826053C (en) 2021-05-25
WO2012110878A2 (en) 2012-08-23
AU2017202628B2 (en) 2019-08-22
KR20130032410A (ko) 2013-04-01
RU2013141487A (ru) 2015-03-27
CN103370622A (zh) 2013-10-23
JP2022043119A (ja) 2022-03-15
US20220229070A1 (en) 2022-07-21
EP2676139A2 (en) 2013-12-25
KR101341538B1 (ko) 2013-12-18
AU2012219184A1 (en) 2013-09-05
EP2676139B1 (en) 2020-05-06
TW201741670A (zh) 2017-12-01
CL2013002361A1 (es) 2014-06-27
CN103370622B (zh) 2018-02-13
KR20120093002A (ko) 2012-08-22
NZ710432A (en) 2017-04-28
EP2676139A4 (en) 2014-12-03
MX2013009380A (es) 2013-12-16
EA201391187A1 (ru) 2013-12-30
JP2014510517A (ja) 2014-05-01
MY175351A (en) 2020-06-22
MX361731B (es) 2018-12-14
JP6798922B2 (ja) 2020-12-09
BR112013020454A8 (pt) 2022-11-29
EA038959B1 (ru) 2021-11-15
WO2012110878A3 (en) 2013-01-31
KR20130136012A (ko) 2013-12-11
DK2676139T3 (da) 2020-06-15
IL227952B (en) 2019-01-31
JP2023115006A (ja) 2023-08-18
TWI668445B (zh) 2019-08-11

Similar Documents

Publication Publication Date Title
UA120697C2 (uk) Спосіб виміру активності природних клітин-кілерів (nk) у зразку цільної крові
JP4532273B2 (ja) 癌に関係するタンパク質
Mroczko et al. Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer
CN109477838B (zh) 利用受体协同活性的nk细胞的活性检查方法及利用其的诊断方法
US20060154311A1 (en) Novel bladder matrix protein peptides and methods of detection of bladder cancer
HK1189273A (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
HK1189273B (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
Jávorházy Role of new biomarkers in the progression of conventional renal cell cancer
JPWO2007026960A1 (ja) Ｍｏｃｓ３遺伝子の治療的又は診断的用途
JP2021018154A (ja) 腫瘍細胞クラスタの検出方法、及び腫瘍細胞クラスタの回収方法、並びに、それらの方法に用いる試薬及び担体固定化分子
JPWO2007037538A1 (ja) Ｓｐｏ１１遺伝子の治療的又は診断的用途
NZ614345B2 (en) Method and use for measurement of nk cell activity
NZ710432B2 (en) Method and use for measurement of nk cell activity
JPWO2007037532A1 (ja) Ｓｒｍｓ遺伝子の治療的又は診断的用途